abstract |
The present invention is situated within the field of novel anti-cancer therapies, specifically within the field of anti-angiogenic molecules. It relates in particular to anti-GB3 antibodies having specific CDR sequences, as well as to the use of anti-GB3 antibodies not coupled to a therapeutic molecule in treating disorders associated with angiogenesis, such as solid tumors. |